written on 27.03.2014

Insmed flails after Phase II Arikayce fail


Insmed's Arikayce missed the primary endpoint in a Phase II clinical trial for the treatment of non-tuberculous mycobacterial (NTM) lung infections, but the company emphasized significant results for the trial's secondary endpoint to keep its stock from…

Latest Reports